文献速递胸部肿瘤

苏特替尼治疗携带罕见EGFR突变NSCLC的多中心开放标签IIb期试验

Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.
PubMed 文献 · J Thorac Oncol · 2026-10-19

该研究评估苏特替尼一线治疗携带罕见EGFR突变(G719X、S768I、L861Q或预设复合突变)的局部晚期或转移性NSCLC的疗效与安全性。结果显示独立评审委员会确认的客观缓解率为70.8%,中位无进展生存期13.7个月,≥3级治疗相关不良事件发生率为42.4%,主要表现为腹泻。苏特替尼达到预设主要终点,具有临床意义的抗肿瘤活性且安全性可控。

要点

  • 苏特替尼在罕见EGFR突变NSCLC中ORR达70.8%,中位PFS为13.7个月。
  • 复合突变患者ORR数值上高于单一突变(84.4% vs 64.1%)。
  • ≥3级TRAE发生率为42.4%,最常见为腹泻(28.3%)。

核心结论

  • 苏特替尼达到预设主要终点,在携带罕见EGFR突变(G719X、S768I、L861Q)的晚期NSCLC中显示出有临床意义的抗肿瘤活性且安全性可控。

研究设计与样本

  • 多中心、开放标签、单臂IIb期试验,纳入99例既往未接受EGFR-TKI治疗的局部晚期或转移性NSCLC患者(疗效可评估96例,安全性分析99例)。
  • 患者口服苏特替尼80 mg每日一次,28天为一周期,直至影像学进展或不可耐受毒性。
  • 主要终点为独立评审委员会评估的客观缓解率,次要终点包括缓解持续时间、疾病控制率、起效时间、无进展生存期、总生存期和安全性。

主要发现

  • 独立评审委员会确认的ORR为70.8%(95%CI 60.7-79.7),疾病控制率为90.6%(95%CI 82.9-95.6)。
  • 中位缓解持续时间为12.0个月(95%CI 9.3-15.7),中位无进展生存期为13.7个月(95%CI 10.9-16.4),中位总生存期未达到(95%CI 22.2-未达到)。
  • 复合突变患者ORR为84.4%,单一罕见突变患者为64.1%;中位PFS分别为13.8个月和11.0个月。
  • 任何级别治疗相关不良事件发生率为97.0%(96/99),≥3级为42.4%(42/99);最常见≥3级TRAE为腹泻28.3%(28/99)、低钾血症8.1%(8/99)、γ-谷氨酰转移酶升高5.1%(5/99)。
  • 34.3%(34/99)患者因TRAE减量,4.0%(4/99)停药,无治疗相关死亡。

临床怎么用

  • 苏特替尼可作为携带G719X、S768I、L861Q或预设复合罕见EGFR突变晚期NSCLC患者的一种潜在一线治疗选择。
  • 治疗期间需重点监测腹泻、低钾血症和肝功能,≥3级腹泻发生率达28.3%,部分患者需减量或停药。

局限性

  • 单臂设计,无对照臂,疗效比较需谨慎解读。
  • 中位总生存期尚未达到,长期生存获益仍需更长时间随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Uncommon EGFR mutations account for approximately 10% of EGFR-altered NSCLC and show heterogeneous sensitivity to EGFR-tyrosine kinase inhibitors (TKIs), with limited prospective evidence to inform first-line therapy. Sutetinib is an irreversible EGFR-TKI. We assessed the safety and antitumor efficacy of sutetinib in patients with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations. METHODS: In this multicenter, open-label, single-arm phase IIb trial, adults with locally advanced or metastatic NSCLC harboring EGFR G719X, S768I, L861Q, or predefined compound mutations and no prior EGFR-TKI therapy were enrolled. Patients received sutetinib 80 mg orally once daily in 28-day cycles until radiographic progression or unacceptable toxicity. Patients who received at least one dose of treatment and were evaluable for efficacy analysis were included in the primary analysis, and all patients who received at least one dose of treatment were included in the safety analysis. The primary endpoint was the objective response rate (ORR), as assessed by the independent review committee. Secondary endpoints included the duration of response, disease control rate, time to response, progression-free survival, overall survival, and safety. RESULTS: From December 9, 2021 to May 5, 2024, 99 patients were enrolled (efficacy-evaluable, N = 96; safety, N = 99). As of the data cutoff in October 2024, the median follow-up was 16.6 months. The independent review committee-confirmed ORR was 70.8% (95% confidence interval [CI]: 60.7-79.7), and the disease control rate was 90.6% (95% CI: 82.9-95.6). The median duration of response was 12.0 months (95% CI: 9.3-15.7), and the median progression-free survival was 13.7 months (95% CI: 10.9-16.4). The median overall survival was not reached (95% CI: 22.2-not reached). The ORR was numerically higher in patients with compound versus solitary uncommon EGFR mutations (84.4% versus 64.1%), with a median progression-free survival of 13.8 versus 11.0 months, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 97.0% (96/99) of patients, and grade ≥ 3 TRAEs occurred in 42.4% (42/99). The most common grade ≥ 3 TRAEs were diarrhea (28.3% [28/99]), hypokalemia (8.1% [8/99]), and increased gamma-glutamyl transferase (5.1% [5/99]). TRAEs led to dose reduction in 34.3% (34/99) and treatment discontinuation in 4.0% (4/99). No treatment-related deaths occurred. CONCLUSIONS: Sutetinib met the prespecified primary endpoint and demonstrated clinically meaningful antitumor activity with a manageable safety profile in advanced NSCLC harboring uncommon EGFR mutations (G719X, S768I, and L861Q). These findings support the use of sutetinib as a potential treatment option for this molecularly heterogeneous population. CLINICAL TRIAL INFORMATION: NCT05168566.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Wu F, Zhang W, Zhao Y, et al. Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial. J Thorac Oncol. 2026. PMID: 42637134. doi:10.1016/j.jtho.2026.104165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。